Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | STTK |
---|---|---|
09:32 ET | 6862 | 3.99 |
09:43 ET | 600 | 3.91 |
09:45 ET | 100 | 3.94 |
09:50 ET | 100 | 3.91 |
09:52 ET | 300 | 3.9 |
09:54 ET | 300 | 3.935 |
09:56 ET | 100 | 3.96 |
09:57 ET | 100 | 3.94 |
09:59 ET | 869 | 3.91 |
10:01 ET | 1700 | 3.86 |
10:03 ET | 500 | 3.87 |
10:06 ET | 200 | 3.87 |
10:08 ET | 700 | 3.86 |
10:10 ET | 200 | 3.87 |
10:12 ET | 400 | 3.86 |
10:14 ET | 2133 | 3.83 |
10:15 ET | 700 | 3.81 |
10:17 ET | 620 | 3.83 |
10:19 ET | 100 | 3.82 |
10:24 ET | 600 | 3.82 |
10:26 ET | 200 | 3.82 |
10:28 ET | 100 | 3.85 |
10:30 ET | 300 | 3.835 |
10:32 ET | 879 | 3.8496 |
10:33 ET | 1000 | 3.82 |
10:35 ET | 1224 | 3.83 |
10:37 ET | 1762 | 3.83 |
10:39 ET | 8950 | 3.78 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Shattuck Labs Inc | 189.7M | -2.0x | --- |
Inhibrx Biosciences Inc | 198.9M | -2.5x | --- |
Pyxis Oncology Inc | 188.4M | -2.3x | --- |
Candel Therapeutics Inc | 187.5M | -5.0x | --- |
Rani Therapeutics Holdings Inc | 192.6M | -2.9x | --- |
Aldeyra Therapeutics Inc | 193.1M | -6.4x | --- |
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $189.7M |
---|---|
Revenue (TTM) | $2.7M |
Shares Outstanding | 47.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.75 |
EPS | $-1.93 |
Book Value | $3.06 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 69.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,327.44% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.